Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa, a biopharmaceutical company and a wholly owned subsidiary of Kyowa Hakko Kirin Co, has licensed its Potelligent technology to GlaxoSmithKline for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity.
Subscribe to our email newsletter
Under the terms of the agreement, BioWa will provide GlaxoSmithKline (GSK) with non-exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.
According to BioWa, Potelligent technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of action for antibody therapeutics.
Masamichi Koike, BioWa’s president and CEO, said: “GSK is recognized as a key player in the field of antibody drug discovery. We believe this represents an important opportunity to promote the development of more effective targeted treatments for debilitating diseases where enhanced ADCC might offer a significant therapeutic benefit.”